Impact of patient sample on costs of events in pharmacoeconomic models

References

• Gold M, Siegel J, Russell L, Weinstein M (Eds). Cost–Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Ramsey S, Willke R, Briggs A et al. Good research practices for cost–effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health8(5), 521 –533 (2005).
   PubMed Web of Science ®Google Scholar
• Motheral B, Brooks J, Clark MA et al. A checklist for retrospective database studies – report of the ISPOR Task Force on Retrospective Databases. Value Health6(2), 90–97 (2003).
   PubMed Web of Science ®Google Scholar
• Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health10(5), 326–335 (2007).
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study. Lancet365(9458), 475–481 (2005).
   PubMed Web of Science ®Google Scholar
• Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann. Rheum. Dis.66(10), 1296–1304 (2007).
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet. Disord.8, 73 (2007).
   PubMed Web of Science ®Google Scholar
• Chen LC, Ashcroft DM. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol. Drug Saf.16(7), 762–772 (2007).
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA296(13), 1633–1644 (2006).
   PubMed Web of Science ®Google Scholar
• Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case–control study. Arch. Intern. Med.165(9), 978–984 (2005).
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med.142(3), 157–164 (2005).
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ308(6921), 81–106 (1994).
   PubMed Web of Science ®Google Scholar
• Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin. Ther.23(7), 1061–1079 (2001).
   PubMed Web of Science ®Google Scholar
• Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: a decision analysis. Arthritis Rheum.47(1), 36–43 (2002).
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective. Am. J. Manag. Care8(17 Suppl.), S502–S517 (2002).
   Google Scholar
• Kamath CC, Kremers HM, Vanness DJ et al. The cost–effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health6(2), 144–157 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Bohn R, Levin R, Avorn J. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J. Rheumatol.30(4), 792–798 (2003).
   PubMed Web of Science ®Google Scholar
• Stacy J, Shaw E, Arledge MD, Howell-Smith D. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan. J. Manag. Care Pharm.9(4), 327–334 (2003).
   PubMedGoogle Scholar
• Rahme E, Barkun AN, Adam V, Bardou M. Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs. Drug Saf.27(13), 1019–1042 (2004).
   PubMed Web of Science ®Google Scholar
• Schaefer M, DeLattre M, Gao X et al. Assessing the cost–effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Curr. Med. Res. Opin.21(1), 47–60 (2005).
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost–effectiveness of competing strategies in varying risk groups. Arthritis Rheum.53(2), 185–197 (2005).
   PubMed Web of Science ®Google Scholar
• Yun HR, Bae SC. Cost–effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatol. Int.25(1), 9–14 (2005).
   PubMed Web of Science ®Google Scholar
• Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol.7, 25 (2007).
   PubMed Web of Science ®Google Scholar
• Claxton K, Briggs A, Buxton MJ et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ336(7638), 251–254 (2008).
   PubMed Web of Science ®Google Scholar
• Claxton K. OFT, VBP: QED? Health Econ.16(6), 545–558 (2007).
   PubMed Web of Science ®Google Scholar